Calypso Medical Technologies, Inc.
RELATED CONTENT
At the surface, the term “advanced visualization†seems nebulous at best. Medical imaging technology continues to develop and advance at a rapid rate, so determining what qualifies as advanced remains a moving target as well. In general, however, the current cutting edge of imaging centers around 3-D/4-D viewing and mobile technology, with different specialties implementing them in unique ways.
June 04, 2015 
Five leading cancer institutions are taking part in the first multi-institutional Phase II study of hypofractionated stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion.
November 23, 2011 
Stereotactic body radiation therapy (SBRT) is an investigational radiotherapy modality for the treatment of localized prostate cancer. Conventional radiotherapy options include prolonged schedules of daily treatment using relatively low radiation doses over a period of six to nine weeks. SBRT offers promise of an expedient, well-tolerated and effective schedule of only five treatments of larger doses for selected patients for whom current conventional treatment options would be either medically contraindicated or refused by the patient for reasons of inconvenience.
November 23, 2011 
September 28, 2011 – Calypso Medical Technologies Inc., developer of real-time localization technology used for precise tumor tracking, announced that the U.S. Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval for its clinical study evaluating real-time tracking of lung cancer tumors during radiation delivery. Patient enrollment is planned at Washington University in St. Louis, and the Cancer Treatment Centers of America in Tulsa, Oklahoma. Investigators in the United States will implant three anchored Beacon transponders in patients’ lungs and use the Calypso System to precisely track tumor location and movement during lung cancer radiation therapy.
September 28, 2011 
September 20, 2011 – Varian Medical Systems and Calypso Medical Technologies announced they have signed a definitive agreement under which Varian will acquire Calypso, a privately owned, Seattle-based developer and supplier of specialized products and software for real-time tumor tracking and motion management during radiosurgery and radiotherapy. The acquisition, which is anticipated to close in early October subject to the satisfaction of certain closing conditions, provides that Varian will pay approximately $10 million for Calypso plus potential earnouts based on unit sales of Calypso products achieved beyond thresholds over the next 30 months.
September 20, 2011 
August 4, 2011—The first multi-institutional study evaluating a new form of radiation treatment for prostate cancer coupled with sophisticated real-time tumor tracking is now underway at the University of Michigan Health System in Ann Arbor, Mich. Principal investigator Daniel A. Hamstra, Ph.D., M.D., assistant professor, department of radiation oncology, along with 10 co-investigators, are evaluating the safety of shortened (hypofractionated) stereotactic body radiation therapy (SBRT) with Calypso Medical’s GPS for the Body technology, used for real-time tracking of cancerous tumors during prostate radiotherapy, and comparing it to conventional radiation treatment.
August 04, 2011 
SBRT is similarly capable of delivering a large, but very precise, dose of radiation through the use of arcs or non-coplanar beams intersecting at the tumor. The accuracy allows clinicians to reduce treatment margins and maximally spare critical normal tissue (including rectum, bladder, urethra and penile bulb) from the high-dose treatment field.
July 18, 2011 
May 23, 2011—Calypso Medical Technologies Inc., developer of GPS for the Body technology used for the precise tracking of cancerous tumors during radiation therapy, is exhibiting at the American Urological Association Annual Meeting (booth 4337) and will discuss recent clinical findings suggesting that the Calypso System can be used to more precisely deliver radiation in post-prostatectomy patients.
May 23, 2011 
February 3, 2011 – The Siteman Cancer Center at the Washington University School of Medicine in St. Louis is the first facility in the world to equip their Calypso System with Dynamic Edge Gating technology.
February 03, 2011 November 3, 2010 – A new system cleared by the U.S. Food and Drug Administration (FDA) automates the response to organ motion that occurs during the delivery of radiation to prostate cancer tumors. Dynamic EdgeT Gating Technology, by Calypso Medical Technologies, is designed to protect healthy tissue from unintended radiation.
November 03, 2010